Glutathione S-Transferase π-Activatable O2-(Sulfonylethyl Derived) Diazeniumdiolates Potently Suppress Melanoma in Vitro and in Vivo

被引:18
作者
Huang, Zhangjian [1 ]
Wu, Jianbing [1 ]
Zou, Yu [1 ]
Yuan, Haoliang [1 ]
Zhang, Yinqiu [1 ]
Fei, Yue [1 ]
Bhardwaj, Atul [2 ]
Kaur, Jatinder [2 ]
Knaus, Edward E. [2 ]
Zhang, Yihua [1 ]
机构
[1] China Pharmaceut Univ, State Key Lab Nat Med, Jiangsu Key Lab Drug Discovery Metab Dis, Ctr Drug Discovery, Nanjing 210009, Jiangsu, Peoples R China
[2] Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB T6G 2E1, Canada
基金
中国国家自然科学基金;
关键词
NITRIC-OXIDE DONORS; RESISTANT OVARIAN-CANCER; ANTICANCER ACTIVITY; THERAPEUTIC AGENTS; ALKYLATING-AGENTS; DRUG-RESISTANCE; PRODRUG; TLK286; NO; PACLITAXEL;
D O I
10.1021/acs.jmedchem.7b01178
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A group of glutathione S-transferase pi (GST pi) activatable O-2-(sulfonylethyl derived) diazeniumdiolates 5-12 were designed and synthesized. These compounds could be activated by GST pi to initiate the beta-elimination reaction, liberating an active vinyl sulfone-based GSH derivative and a diazeniumdiolate anion which subsequently releases NO in situ. The most active compound 6 released relatively high levels of NO and inhibited proliferation of melanoma B16 cells, superior to a diazeniumdiolate-based anticancer agent JS-K (1). Importantly, 6 had 8-fold less inhibitory activity against normal epithelial JB6 Cl 30-7b cells. The inhibitory activity of 6 could be diminished by an NO scavenger or GST pi inhibitor. Furthermore, 6 induced nitration of mitochondrial tyrosine in B16 cells and inoculated B16 tumors in mice, which might be responsible for oxidation of protein leading to tumor suppression. Finally, 6 significantly retarded the B16 cells growth in a mouse xenograft model. These findings suggest that 6 may have a potential to treat melanoma.
引用
收藏
页码:1833 / 1844
页数:12
相关论文
共 58 条
[1]  
ANDERSON ME, 1994, METHOD ENZYMOL, V234, P492
[2]   Structure, catalytic mechanism, and evolution of the glutathione transferases [J].
Armstrong, RN .
CHEMICAL RESEARCH IN TOXICOLOGY, 1997, 10 (01) :2-18
[3]  
ARNOLD H, 1961, ARZNEIMITTEL-FORSCH, V11, P143
[4]   Therapeutic potential of nitric oxide in cancer [J].
Bonavida, Benjamin ;
Khineche, Soraya ;
Huerta-Yepez, Sara ;
Garban, Hermes .
DRUG RESISTANCE UPDATES, 2006, 9 (03) :157-173
[5]   NITRIC-OXIDE - A PHYSIOLOGICAL MESSENGER MOLECULE [J].
BREDT, DS ;
SNYDER, SH .
ANNUAL REVIEW OF BIOCHEMISTRY, 1994, 63 :175-195
[6]   The yin and yang of nitric oxide in cancer progression [J].
Burke, Amy J. ;
Sullivan, Francis J. ;
Giles, Francis J. ;
Glynn, Sharon A. .
CARCINOGENESIS, 2013, 34 (03) :503-512
[7]   Hybrid Molecule from O2-(2,4-Dinitrophenyl)diazeniumdiolate and Oleanolic Acid: A Glutathione S-Transferase π-Activated Nitric Oxide Prodrug with Selective Anti-Human Hepatocellular Carcinoma Activity and Improved Stability [J].
Fu, Junjie ;
Liu, Ling ;
Huang, Zhangjian ;
Lai, Yisheng ;
Ji, Hui ;
Peng, Sixun ;
Tian, Jide ;
Zhang, Yihua .
JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (11) :4641-4655
[8]   The role of nitric oxide in tumour progression [J].
Fukumura, Dai ;
Kashiwagi, Satoshi ;
Jain, Rakesh K. .
NATURE REVIEWS CANCER, 2006, 6 (07) :521-534
[9]   Electrophilic natural products and their biological targets [J].
Gersch, Malte ;
Kreuzer, Johannes ;
Sieber, Stephan A. .
NATURAL PRODUCT REPORTS, 2012, 29 (06) :659-682
[10]   The glutathione S-Transferase supergene family: Regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance [J].
Hayes, JD ;
Pulford, DJ .
CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1995, 30 (06) :445-600